SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001104659-21-045912
Filing Date
2021-04-02
Accepted
2021-04-02 10:33:46
Documents
1
Period of Report
2021-04-01

Document Format Files

Seq Description Document Type Size
1 OWNERSHIP DOCUMENT tm2111994-1_4seq1.html 4  
1 OWNERSHIP DOCUMENT tm2111994-1_4seq1.xml 4 3112
  Complete submission text file 0001104659-21-045912.txt   4579
Mailing Address C/O ARBUTUS BIOPHARMA 100-8900 GLENLYON PARKWAY BURNABY A1 V5J 5J8
Business Address
HASTINGS DAVID C (Reporting) CIK: 0001237401 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-38670 | Film No.: 21800820

Mailing Address 35 GATEHOUSE DRIVE WALTHAM MA 02451
Business Address 35 GATEHOUSE DRIVE WALTHAM MA 02451 (781) 810-0120
Entasis Therapeutics Holdings Inc. (Issuer) CIK: 0001724344 (see all company filings)

IRS No.: 824592913 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations